All In Biotech

Free tool

FAERS Monitor: Cystadrops

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211302 or its brand name (Cystadrops, Cysteamine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

240

Serious

157

65% of reports

Hospitalization

96

Death reported

19

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye irritation41
  • eye pain26
  • death15
  • vision blurred14
  • vomiting14
  • ocular hyperaemia13
  • off label use9
  • amino acid level increased8
  • corneal neovascularisation8
  • pneumonia8
  • treatment noncompliance8
  • dehydration7
  • diarrhoea7
  • inappropriate schedule of product administration7
  • photophobia7

Reports by year received

View as table
YearReports
20152
20161
20171
20181
20193
202021
202140
202240
202347
202457
202518
20269

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,919 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
corneal neovascularisationSignal82936.41468.419,963
amino acid level increasedSignal8954.8481.36,627
eye irritationSignal4162.547.32,424
eye painSignal2640.428.1962
photophobiaSignal732.615.7184
ocular hyperaemiaSignal1324.014.2265
treatment noncomplianceSignal812.86.576
vision blurredSignal148.95.491
dehydrationSignal74.62.216
inappropriate schedule of product administrationSignal73.41.610
vomitingSignal142.61.613
pneumonia82.21.14
death151.50.92
diarrhoea71.00.50
off label use90.90.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.